Core Viewpoint - CEG (协鑫科技) has turned profitable in Q3 2025 for its photovoltaic materials segment, reporting a profit of 960 million RMB, which includes a post-tax profit of 640 million RMB from the sale of its associate company, Xinhua Semiconductor [1] Group 1: Financial Performance - CEG's photovoltaic materials segment achieved a profit of 960 million RMB in Q3 2025, marking a turnaround from previous losses [1] - The increase in profit is attributed to a significant rise in polysilicon prices, which increased from a low of 34,000 RMB per ton to the current price of 50,000 RMB per ton since late July [1] - The company's operating rate has increased, which has helped to dilute unit depreciation and expenses, contributing to the profitability of the granular silicon business [1] Group 2: Market Outlook - CEG's net profit forecast has been raised by the research firm, with a target price adjustment to 1.54 HKD based on a 2026 price-to-earnings ratio of 16 times [1] - The firm maintains a "Buy" rating for CEG, indicating a positive outlook for the company's future performance [1]

Core Viewpoint - The report from CMB International maintains a target price of HKD 183 for Kangfang Biopharma (09926) and expresses a long-term bullish outlook with a "Buy" recommendation, highlighting the company's overseas development progress and upcoming catalysts in the next 1-2 years [1] Group 1: Company Performance - Kangfang Biopharma's overseas development is gaining momentum, with significant catalysts expected in the near future [1] - The report notes that Summit Therapeutics has recently announced an expansion of the overseas research scale for Ivosidenib [1] Group 2: Clinical Data - Ivosidenib's second head-to-head Phase III study has yielded strong positive data, showing that the median progression-free survival (PFS) is significantly better than other PD-1 monotherapy drugs [1] - The absolute improvement in PFS for Ivosidenib compared to PD-1 exceeds the improvement seen with traditional chemotherapy [1] Group 3: Sales Expectations - The report maintains an expectation of peak sales in mainland China at RMB 7.1 billion [1]

Group 1 - The core viewpoint of the article indicates that the e-commerce sector is experiencing growth, with adjusted online retail sales in the physical e-commerce sector increasing by 7.5% year-on-year in Q3 [1] - The postal bureau anticipates a 12% year-on-year increase in express delivery volume in September, indicating stable growth [1] - The extended promotional period for the Double Eleven shopping festival is expected to drive growth in instant retail [1] Group 2 - The report forecasts that Alibaba's e-commerce GMV growth in September will align with the market average, while customer management revenue (CMR) growth will outpace GMV growth [1] - JD Group is expected to maintain steady retail growth in Q3, with improvements in average unit economics (UE) for its delivery services [1] - Kuaishou is projected to achieve a 15% year-on-year increase in e-commerce GMV in Q3 [1] Group 3 - Pinduoduo is expected to see marginal improvements in the second half of the year due to supportive policies and national subsidies [1] - The report provides price-to-earnings ratios for 2025: Alibaba at 19.7x, JD at 11.8x, Pinduoduo at 12.5x, and Kuaishou at 14.1x [1] - Alibaba's e-commerce market share is stabilizing, with a focus on restructuring its e-commerce framework through investments in instant retail and AI [1]

Core Viewpoint - The report from CMB International maintains a target price of HKD 183 for Kangfang Biotech (09926) and continues to recommend a "Buy" rating, expressing long-term confidence in the company due to its overseas development progress and upcoming catalysts in the next 1-2 years [1] Group 1 - The company is experiencing significant advancements in its overseas development, with a focus on expanding research efforts [1] - Summit Therapeutics has recently announced an expansion of the overseas research scale for Ivosidenib [1] - Ivosidenib's second head-to-head Phase III study has yielded strong positive data, showing a median progression-free survival (PFS) that significantly outperforms other PD-1 monotherapy drugs [1] Group 2 - The absolute improvement in PFS for Ivosidenib compared to PD-1 has exceeded the improvement seen with traditional chemotherapy [1] - The report maintains an expectation of peak sales in mainland China at RMB 7.1 billion [1]

Core Viewpoint - The report from交银国际 indicates that JD Group is expected to achieve a 13% year-on-year increase in total revenue for Q3, reaching 294.62 billion RMB, aligning with market expectations. The adjusted net profit is projected to be 4.2 billion RMB, with a profit margin of 1.4%, which is an improvement compared to 5.1% in the same period last year and 2.1% in Q2 [1] Revenue and Profit Forecast - Total revenue for JD Group in Q3 is anticipated to be 294.62 billion RMB, reflecting a 13% year-on-year growth [1] - The adjusted net profit is expected to be 4.2 billion RMB, corresponding to a profit margin of 1.4%, which is better than the previous year's 5.1% and Q2's 2.1% [1] Business Segment Performance - The retail business is projected to maintain steady growth, with a year-on-year increase of 10%, driven by double-digit growth in daily necessities, while the growth rate for electronics is expected to slow due to a high base from last year [1] - The order volume for the food delivery service in Q3 is expected to exceed that of Q2, with improvements in fulfillment efficiency and subsidy efficiency leading to a reduction in losses [1] - There is an expectation of increased cross-selling between the food delivery service and retail, with potential for more synergies during the e-commerce promotional period in Q4 [1]

Core Viewpoint - The report from CMB International indicates that JD Group (09618, JD.US) is expected to achieve a 13% year-on-year revenue growth in Q3, reaching 294.62 billion RMB, aligning with market expectations [1] Revenue and Profit Forecast - Total revenue for Q3 is projected at 294.62 billion RMB, reflecting a 13% increase compared to the previous year, consistent with institutional expectations [1] - Adjusted net profit is anticipated to be 4.2 billion RMB, corresponding to a profit margin of 1.4%, which is an improvement from 5.1% in the same period last year and 2.1% in Q2 [1] Business Segment Performance - The retail business is expected to maintain steady growth, with a year-on-year increase of 10%, driven by double-digit growth in daily necessities, while the growth rate for electronics is slowing due to a high base effect from last year [1] - The third quarter saw an increase in the order volume for food delivery compared to Q2, with improvements in fulfillment efficiency and subsidy efficiency leading to a reduction in losses [1] Future Outlook - The company is expected to further enhance cross-selling with retail during the fourth quarter's e-commerce promotional period, potentially leading to more synergistic effects [1]

Core Viewpoint - The report from交银国际 maintains a leading rating for the securities industry, highlighting high investment value and potential opportunities due to short-term market fluctuations [1] Group 1: Earnings and Growth - The brokerage firms are expected to see a 20% quarter-on-quarter increase in profits for Q3, with year-on-year growth anticipated to remain above 50% [1] - In the first half of the year, listed brokerages reported a 51.5% year-on-year profit increase, with Q1 and Q2 showing growth rates of 53% and 50% respectively [1] - The average daily trading volume of A-shares for the first three quarters was 1.62 trillion RMB, reflecting a year-on-year increase of 104.6%, with Q3 expected to show a 208.8% year-on-year growth due to a low base [1] Group 2: IPO and Fundraising - The A-share IPO fundraising amount for the first three quarters reached 77.3 billion RMB, a 62% year-on-year increase, significantly higher than the 15% growth in the first half [2] - Total equity fundraising amounted to 896.2 billion RMB, a 3.4 times increase year-on-year, with 376.2 billion RMB (an 84% increase) when excluding the directed issuance by state-owned banks [2] - The top three firms in A-share IPO underwriting amounts were 中金, 国泰海通, and 华泰, while 中金 led in Hong Kong stock underwriting [2] Group 3: Market Performance and Valuation - The A-share market saw significant gains in Q3, with the CSI 300 index rising by 17.9% in the first three quarters, while small-cap indices, particularly the ChiNext and Sci-Tech 50 indices, exceeded 50% growth [2] - The current price-to-book ratio for the A-share securities industry index is 1.45, which is below the historical median of 1.51, indicating that the sector is still undervalued despite strong expected earnings growth [2]

Core Insights - China has implemented export controls on certain lithium battery materials and equipment, which is expected to lengthen the overseas factory establishment cycle for Chinese battery companies and create a more orderly expansion of overseas capacity [3] - The export controls are anticipated to increase barriers for lithium battery and material exports, potentially alleviating price competition for Chinese companies in overseas markets and improving profitability for leading firms with overseas capacity [3] - The production data for October indicates a strong increase in battery production, driven by seasonal demand and robust energy storage needs, with an average industry operating rate nearing 90% [4] Industry Performance - In September, the domestic power battery installation volume in China continued to grow, with a total of 76.0 GWh installed, reflecting a year-on-year increase of 39.5% and a month-on-month increase of 21.6% [1] - The total battery exports in September reached 26.7 GWh, marking a month-on-month increase of 28.3% and accounting for 18.2% of total sales [2] - The export volume of power batteries specifically rose to 17.6 GWh, representing a significant year-on-year increase of 50.9% [2] Production and Demand Trends - October's battery production is projected to rise by 10% compared to September, driven by strong seasonal demand and energy storage requirements [4] - The newly added energy storage bidding scale in China for the first eight months of 2025 reached 292 GWh, showing a year-on-year growth of 104% [4] - The price of lithium hexafluorophosphate has surpassed 70,000 yuan per ton, indicating strong bargaining power for leading battery companies in the downstream market [4] Investment Focus - Companies with cost and technological advantages, as well as those with leading overseas expansion strategies, such as CATL (300750.SZ), are recommended for investment consideration [5]

Core Viewpoint - The report from CMB International indicates a positive investment rating for the mainland automotive industry, driven by a significant increase in the penetration rate of new energy vehicles, which reached 57.8% in September. The firm anticipates a strong sales performance in the fourth quarter due to various market factors [1] Group 1: Market Performance - In September, the retail sales of passenger vehicles in China reached 2.241 million units, representing a year-on-year increase of 6.3% and a month-on-month increase of 11% [1] - Cumulative retail sales of passenger vehicles from January to September 2025 totaled 17.005 million units, reflecting a year-on-year growth of 9.2% [1] Group 2: Future Outlook - The adjustment of the new energy vehicle purchase tax exemption policy in 2026 is expected to stimulate consumer purchases towards the end of the year, alongside the traditional peak sales seasons of "Golden September and Silver October" [1] - The automotive market is anticipated to enter a consumption lull after the fourth quarter sales surge, necessitating cautious monitoring of stock price fluctuations in the sector [1] Group 3: Company Highlights - Xpeng Motors (09868) is expected to boost sales and gross margins with the launch of its new P7 and extended-range models [1] - Geely Automobile (00175) is focusing on internal resource integration following the privatization of its Zeekr brand [1] - Seres is expanding its high-end market presence and improving profitability with its Aito series [1]

HKG4106328 164374-0002 CONTENTS | Clause | | Page | | --- | --- | --- | | 1. | DEFINITIONS AND INTERPRETATION | 1 | | 2. | CONDITIONALITY | 3 | | 3. | GENERAL TERMS FOR TRANSACTIONS | 3 | | 4. | REPRESENTATIONS, WARRANTIES AND UNDERTAKINGS | 4 | | 5. | DURATION AND TERMINATION | 4 | | 6. | NOTICES | 5 | | 7. | GENERAL | 5 | | 8. | GOVERNING LAW AND JURISDICTION | 6 | HKG4106328 164374-0002 THIS AGREEMENT is made on 25 April 2017 25 April 2017 and BOCOM INTERNATIONAL HOLDINGS COMPANY LIMITED BANK OF COMMUNIC ...